Barclays PLC Has $189,000 Stake in PepGen Inc. (NASDAQ:PEPG)

Barclays PLC increased its stake in shares of PepGen Inc. (NASDAQ:PEPG) by 318.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 21,971 shares of the company’s stock after acquiring an additional 16,723 shares during the period. Barclays PLC owned 0.07% of PepGen worth $189,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Janus Henderson Group PLC increased its holdings in shares of PepGen by 331.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after acquiring an additional 1,794,641 shares during the last quarter. Suvretta Capital Management LLC boosted its stake in PepGen by 9.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after purchasing an additional 140,000 shares during the period. Walleye Capital LLC bought a new stake in PepGen during the 3rd quarter valued at approximately $519,000. Wellington Management Group LLP boosted its stake in PepGen by 76.9% during the 3rd quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock valued at $346,000 after purchasing an additional 17,618 shares during the period. Finally, Jane Street Group LLC boosted its stake in PepGen by 29.1% during the 3rd quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock valued at $237,000 after purchasing an additional 6,254 shares during the period. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Price Performance

PEPG stock opened at $2.08 on Wednesday. The business has a fifty day moving average price of $4.18 and a 200 day moving average price of $8.12. The stock has a market capitalization of $67.81 million, a price-to-earnings ratio of -0.70 and a beta of 1.66. PepGen Inc. has a fifty-two week low of $2.07 and a fifty-two week high of $19.30.

PepGen (NASDAQ:PEPG) last released its earnings results on Thursday, November 7th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.21. On average, equities analysts expect that PepGen Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Bank of America downgraded PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a research note on Monday, December 16th. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of PepGen in a research note on Friday, November 8th. Finally, Wedbush reduced their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.